Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.41 |
| ▸ | GABRP | O00591 | 6/20 | 0.41 |
| ▸ | GABRD | O14764 | 6/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.41 |
| ▸ | GABRE | P78334 | 6/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883634 | 0.85 | DGAT1 (0.43) | HIF1AKDM4EALDH1A1DGAT1GSK3A | |
| SCHEMBL29792056 | 0.85 | DGAT1 (0.43) | HIF1AKDM4EALDH1A1DGAT1GSK3A | |
| SCHEMBL23033308 | 0.81 | MAPT (0.40) | NPC1MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23012894 | 0.81 | RAB9A (0.39) | UCHL1HIF1ACYP1A2GABRA1GABRG2 | |
| SCHEMBL18274813 | 0.80 | KDM4E (0.46) | HIF1AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL22685876 | 0.80 | ALDH1A1 (0.40) | HIF1AALDH1A1DGAT1GSK3AGSK3B | |
| SCHEMBL29504593 | 0.80 | ALDH1A1 (0.40) | HIF1AALDH1A1DGAT1GSK3AGSK3B | |
| SCHEMBL2315142 | 0.80 | ALDH1A1 (0.40) | HIF1AALDH1A1DGAT1GSK3AGSK3B | |
| SCHEMBL16611149 | 0.80 | DGAT1 (0.49) | UCHL1HIF1ACYP1A2GABRA1GABRG2 | |
| SCHEMBL18274832 | 0.80 | HIF1A (0.39) | UCHL1HIF1ANPC1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891377-B1 | Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10280142-B2 | Bipyridyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2019-05-07 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3101004-B1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-2970334-B1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9908852-B2 | Bipyridyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-06 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3229801-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014143672-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN IDEC MA INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891377-B1 | Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | CSNK2A2, CKS2, CSNK2A3 | UCHL1 1633/4885HIF1A 995/4885CYP1A2 3765/4885 |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK4, IRAK1, IRAK2 | UCHL1 4393/4885HIF1A 2872/4885CYP1A2 2273/4885 |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | UCHL1 4531/4885HIF1A 313/4885CYP1A2 133/4885 |
| US-20180030036-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | UCHL1 4240/4885HIF1A 387/4885CYP1A2 1111/4885 |
| US-10280142-B2 | Bipyridyl compound | CBR1, NR0B2, ERBB2 | UCHL1 4531/4885HIF1A 313/4885CYP1A2 133/4885 |
| US-10189819-B2 | Factor IXa inhibitors | F9, TFPI, F12 | UCHL1 4240/4885HIF1A 387/4885CYP1A2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.